ENG | SWE
VC investment portfolio
The associated companies in Allenex’s VC portfolio.
Medical Device
|
|
BioResonator has developed a non-invasive biomedical sensor for measuring intraocular eye pressure, a procedure which is regularly done at eye clinics, optometrists and qualified opticians to diagnose glaucoma. Product is launced in Europe. For more information visit www.bioresonator.com |
|
|
Biovator develops tests for the predictive identification of allergenicity and immunogenicity in chemical substances. The technology has the potential to substantially reduce the need for animal testing, since it is less expensive, quicker to use and provides more reliable results. For more information please visit www.biovator.se |
|
|
Likvor’s CE marked instrument, CELDA™, has been developed to measure the pressure and flow dynamics of the cerebrospinal fluid. The instrument enables people suffering from NPH (normal pressure hydrocephalus) to receive an accurate diagnosis. For more information please visit www.likvor.com |
|
|
ONCOlog Medical develops, markets and supports a number of products and systems solutions used to enhance the quality of care and increase the efficacy of radiotherapy treatment for cancer. The company’s patient logistics system PatLog® increases patient flow at medical centers, while also improving the quality of care for individual patients and enhancing the center’s operations. ONCOlog’s products are registered for sale in Europe and in the US. For more information please visit www.onclogmedical.com |
|
|
Pharmacolog develops systems enabling hospitals to control that the correct type, amount and concentration of drug is used in infusion and injection solutions. The company’s product DrugLog™ is designed to reduce the number of medication errors, which has been identified as one of the most serious healthcare problems both in the U.S. and Europe. For more information please visit www.pharmacolog.se |
Drug Development and Biotechnology
|
|
AnaMar’s focus is on identifying and treating degenerative joint diseases, in particular rheumatoid arthritis. Today, the company’s project portfolio comprises five drug candidates and two biomarkers under development. The company is also marketing two biomarkers used in drug development and other types of research. In 2010, AnaMar completed phase I clinical trials on the AMAP102 compound for rheumatoid arthritis. For more information please visit www.anamar.com |
